Allergan PE Ratio 2006-2018 | AGN

Current and historical p/e ratio for Allergan (AGN) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Allergan PE ratio as of April 22, 2019 is 8.40.
Allergan PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-04-22 140.26 0.00
2018-12-31 132.95 $-15.32 0.00
2018-09-30 188.65 $6.39 29.52
2018-06-30 164.47 $-5.57 0.00
2018-03-31 165.28 $-6.55 0.00
2017-12-31 159.93 $-13.42 0.00
2017-09-30 199.58 $-22.50 0.00
2017-06-30 236.00 $28.15 8.38
2017-03-31 231.23 $29.08 7.95
2016-12-31 202.67 $37.41 5.42
2016-09-30 222.26 $35.83 6.20
2016-06-30 223.02 $10.54 21.16
2016-03-31 258.67 $11.18 23.14
2015-12-31 301.58 $8.86 34.04
2015-09-30 262.31 $7.88 33.29
2015-06-30 292.86 $-9.36 0.00
2015-03-31 287.22 $-8.28 0.00
2014-12-31 248.42 $-5.88 0.00
2014-09-30 232.85 $-3.98 0.00
2014-06-30 215.26 $0.46 467.95
2014-03-31 198.66 $-4.09 0.00
2013-12-31 162.13 $-5.43 0.00
2013-09-30 138.93 $-4.36 0.00
2013-06-30 121.73 $-4.25 0.00
2013-03-31 88.83 $-0.47 0.00
2012-12-31 82.94 $0.75 110.59
2012-09-30 82.13 $1.29 63.67
2012-06-30 71.36 $1.23 58.01
2012-03-31 64.67 $2.14 30.22
2011-12-31 58.19 $2.07 28.11
2011-09-30 65.82 $1.47 44.78
2011-06-30 66.28 $1.14 58.14
2011-03-31 54.02 $1.29 41.87
2010-12-31 49.81 $1.50 33.21
2010-09-30 40.80 $1.86 21.94
2010-06-30 39.13 $2.19 17.87
2010-03-31 40.28 $2.07 19.46
2009-12-31 38.20 $1.93 19.79
2009-09-30 35.34 $1.92 18.40
2009-06-30 32.49 $2.00 16.25
2009-03-31 30.00 $2.08 14.42
2008-12-31 25.62 $2.10 12.20
2008-09-30 27.49 $1.94 14.17
2008-06-30 26.20 $1.63 16.08
2008-03-31 28.28 $1.43 19.77
2007-12-31 26.17 $1.27 20.61
2007-09-30 31.25 $-3.87 0.00
2007-06-30 31.37 $-3.87 0.00
2007-03-31 25.49 $-4.33 0.00
2006-12-31 25.10 $-4.39 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $46.669B $15.787B
Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $14.602B 5.04
Mylan (MYL) United Kingdom $13.853B 5.86
Bausch Health Cos (BHC) Canada $8.091B 5.75
Dr Reddy's Laboratories (RDY) India $6.770B 27.00
Supernus Pharmaceuticals (SUPN) United States $1.887B 17.51
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.523B 2.47
Amphastar Pharmaceuticals (AMPH) United States $0.943B 87.65
Homology Medicines (FIXX) United States $0.832B 0.00
CymaBay Therapeutics (CBAY) United States $0.718B 0.00
Voyager Therapeutics (VYGR) United States $0.626B 0.00
Assembly Biosciences (ASMB) United States $0.423B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.410B 0.00
Akorn (AKRX) United States $0.348B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.172B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.170B 0.00
Sol-Gel Technologies (SLGL) Israel $0.132B 0.00
Acasti Pharma (ACST) Canada $0.074B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.061B 0.00
Agile Therapeutics (AGRX) United States $0.060B 0.00
Teligent (TLGT) United States $0.044B 0.00
Aevi Genomic Medicine (GNMX) United States $0.014B 0.00
Evoke Pharma (EVOK) United States $0.013B 0.00